Stocktwits on MSN

Sellas Life Sciences draws significant retail buzz as traders eye REGAL phase 3 catalyst – SLS stock soars 15%

Sellas’ CEO referenced the company’s Phase 3 REGAL trial in a LinkedIn post, following its December update that the final analysis was approaching for GPS as a therapy in AML. ・Anson Funds Management ...
The Globe and Mail

SELLAS Raises $26.5 Million Through Warrant Exercises

SELLAS Life Sciences Group ( (SLS)) just unveiled an update. Subsequent to December 31, 2025, SELLAS Life Sciences Group, a biopharmaceutical company, received approximately $26.5 million in cash ...